Literature DB >> 28365573

Serum Levels of Interleukin 33 and Soluble ST2 Are Associated with the Extent of Disease Activity and Cutaneous Manifestations in Patients with Active Adult-onset Still's Disease.

Jae Ho Han1,2, Chang-Hee Suh1,2, Ju-Yang Jung1,2, Mi-Hyun Ahn1,2, Ji Eun Kwon1,2, Hyunee Yim1,2, Hyoun-Ah Kim3,4.   

Abstract

OBJECTIVE: Interleukin 33 (IL-33), a member of the IL-1 family and a ligand of the orphan receptor ST2, plays key roles in innate and adaptive immunity. We examined the associations between IL-33/ST2 levels and clinical manifestations of patients with active adult-onset Still's disease (AOSD).
METHODS: Blood samples were collected from 40 patients with active AOSD, 28 patients with rheumatoid arthritis (RA), and 27 healthy controls (HC). The serum levels of IL-33 and soluble ST2 were determined using ELISA. Expression levels of IL-33 and ST2 in biopsy specimens obtained from 34 AOSD patients with rash were immunohistochemically investigated.
RESULTS: IL-33 levels of patients with AOSD were higher than those of patients with RA and HC. Soluble ST2 levels of patients with AOSD were higher than those of HC, but not of patients with RA. Serum IL-33 levels correlated with systemic score, erythrocyte sedimentation rate, ferritin levels, and aspartate transaminase levels. However, serum soluble ST2 levels correlated only with ferritin levels. The numbers of inflammatory cells expressing IL-33 and ST2 were elevated in skin lesions of patients with AOSD compared to HC, but did not differ from those of the skin lesions of eczema or psoriasis.
CONCLUSION: We found significantly higher serum IL-33 and soluble ST2 levels in patients with active AOSD. Results indicate that the IL-33/ST2 signaling pathway may play a role in the pathogenesis of the acute inflammation and skin manifestations associated with AOSD.

Entities:  

Keywords:  ADULT ONSET STILL’S DISEASE; BIOMARKER; DISEASE ACTIVITY; INTERLEUKIN 33; SOLUBLE ST2

Mesh:

Substances:

Year:  2017        PMID: 28365573     DOI: 10.3899/jrheum.170020

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Interleukin-33 modulates inflammation in endometriosis.

Authors:  Jessica E Miller; Stephany P Monsanto; Soo Hyun Ahn; Kasra Khalaj; Asgerally T Fazleabas; Steven L Young; Bruce A Lessey; Madhuri Koti; Chandrakant Tayade
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

Review 2.  Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review.

Authors:  Meng-Yan Wang; Jin-Chao Jia; Cheng-De Yang; Qiong-Yi Hu
Journal:  Chin Med J (Engl)       Date:  2019-12-05       Impact factor: 2.628

3.  Association of Inflammatory Markers/Cytokines with Cardiovascular Risk Manifestation in Patients with Endometriosis.

Authors:  Uzma Rafi; Shaaf Ahmad; Syeda Shazia Bokhari; Muhammad Amir Iqbal; Amna Zia; Muhammad Amjad Khan; Nabila Roohi
Journal:  Mediators Inflamm       Date:  2021-10-31       Impact factor: 4.711

Review 4.  New insights on multigenic autoinflammatory diseases.

Authors:  Petros Efthimiou; Olga Petryna; Priscila Nakasato; Apostolos Kontzias
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-09-03       Impact factor: 3.625

5.  Alarmins HMGB1, IL-33, S100A7, and S100A12 in Psoriasis Vulgaris.

Authors:  Pavel Borsky; Zdenek Fiala; Ctirad Andrys; Martin Beranek; Kvetoslava Hamakova; Andrea Malkova; Tereza Svadlakova; Jan Krejsek; Vladimir Palicka; Lenka Borska; Vit Rehacek
Journal:  Mediators Inflamm       Date:  2020-04-15       Impact factor: 4.711

Review 6.  Adult-Onset Still's Disease: Novel Biomarkers of Specific Subsets, Disease Activity, and Relapsing Forms.

Authors:  Beatrice Maranini; Giovanni Ciancio; Marcello Govoni
Journal:  Int J Mol Sci       Date:  2021-12-11       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.